Quantitative Systematic Strategies LLC decreased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 13.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,136 shares of the biopharmaceutical company’s stock after selling 6,315 shares during the period. Bristol-Myers Squibb comprises approximately 0.7% of Quantitative Systematic Strategies LLC’s holdings, making the stock its 15th biggest holding. Quantitative Systematic Strategies LLC’s holdings in Bristol-Myers Squibb were worth $2,495,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its holdings in Bristol-Myers Squibb by 108.5% during the 2nd quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after acquiring an additional 7,020,200 shares in the last quarter. Franklin Resources Inc. grew its holdings in Bristol-Myers Squibb by 185.2% during the 2nd quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after acquiring an additional 3,960,191 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Bristol-Myers Squibb by 2,990.5% during the 2nd quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after acquiring an additional 3,516,536 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Bristol-Myers Squibb by 42,071.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after acquiring an additional 3,323,649 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Bristol-Myers Squibb by 18.7% in the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after buying an additional 2,451,390 shares during the period. 69.82% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have recently commented on BMY. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a report on Monday, December 11th. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a report on Tuesday, December 5th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Finally, Credit Suisse Group reaffirmed a “hold” rating and issued a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $64.93.

In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $62.41 on Friday. The firm has a market cap of $102,154.63, a PE ratio of 21.09, a P/E/G ratio of 2.37 and a beta of 1.18. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.77 earnings per share. equities analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be given a $0.40 dividend. The ex-dividend date is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.56%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 61.42%.

WARNING: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://theolympiareport.com/2017/12/17/quantitative-systematic-strategies-llc-has-2-50-million-position-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with Analyst Ratings Network's FREE daily email newsletter.